Literature DB >> 18208497

HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?

J T Blackard1, K E Sherman.   

Abstract

Because of major advances in the treatment of HIV/AIDS, HIV-positive persons now live longer, healthier lives; however, hepatitis C virus (HCV) is increasingly recognized as a major cause of morbidity and mortality in this population. Among HCV-infected persons, HIV co-infection is associated with increased HCV RNA levels, increased hepatic inflammation and fibrosis, and more rapid progression to cirrhosis and end-stage liver disease. Compounding this problem are reduced HCV treatment response rates among HCV/HIV co-infected persons. Moreover, antiretroviral therapy used to suppress HIV replication is often associated with a paradoxical increase in HCV RNA levels, as well as hepatotoxicity. Despite the adverse clinical consequences of HCV/HIV co-infection, the mechanisms by which these two viruses interact at the cellular level remain largely unexplored. This review focuses on the evidence demonstrating direct infection of hepatocytes by HIV, as well as the indirect mechanisms by which HIV may regulate HCV replication at the cellular level. A comprehensive understanding of virus-virus and virus-cell interactions is critical to the development of novel treatment strategies to combat HCV/HIV co-infection.

Entities:  

Mesh:

Year:  2008        PMID: 18208497      PMCID: PMC3526832          DOI: 10.1111/j.1365-2893.2008.00970.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  94 in total

1.  Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C.

Authors:  F Kusano; Y Tanaka; F Marumo; C Sato
Journal:  Lab Invest       Date:  2000-03       Impact factor: 5.662

2.  Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1.

Authors:  Sarah L Pett; Greg J Dore; Robert J Fielden; David A Cooper
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

3.  Rift Valley Fever virus in mice. II. Adsorption and multiplication of virus.

Authors:  C A MIMS
Journal:  Br J Exp Pathol       Date:  1956-04

4.  Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.

Authors:  B Soto; A Sánchez-Quijano; L Rodrigo; J A del Olmo; M García-Bengoechea; J Hernández-Quero; C Rey; M A Abad; M Rodríguez; M Sales Gilabert; F González; P Mirón; A Caruz; F Relimpio; R Torronteras; M Leal; E Lissen
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

5.  Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.

Authors:  Georg M Lauer; Tam N Nguyen; Cheryl L Day; Gregory K Robbins; Theresa Flynn; Katherine McGowan; Eric S Rosenberg; Michaela Lucas; Paul Klenerman; Raymond T Chung; Bruce D Walker
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  An in vitro model of hepatitis C virion production.

Authors:  Theo Heller; Satoru Saito; Jonathan Auerbach; Tarice Williams; Tzivia Rachel Moreen; Allison Jazwinski; Brian Cruz; Neha Jeurkar; Ronda Sapp; Guangxiang Luo; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-08       Impact factor: 11.205

7.  Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.

Authors:  Raymond T Chung; Scott R Evans; Yijun Yang; Dickens Theodore; Hernan Valdez; Rebecca Clark; Cecilia Shikuma; Thomas Nevin; Kenneth E Sherman
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

8.  Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes.

Authors:  Anuradha Balasubramanian; Ramesh K Ganju; Jerome E Groopman
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

9.  Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.

Authors:  Katie B Anderson; Jodie L Guest; David Rimland
Journal:  Clin Infect Dis       Date:  2004-10-25       Impact factor: 9.079

Review 10.  Therapeutic issues in HIV/HCV-coinfected patients.

Authors:  M S Sulkowski; Y Benhamou
Journal:  J Viral Hepat       Date:  2007-06       Impact factor: 3.728

View more
  42 in total

1.  HIV and liver disease forum: conference proceedings.

Authors:  Kenneth E Sherman; Marion Peters; Margaret James Koziel
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

2.  Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen.

Authors:  David M Iser; Nadia Warner; Peter A Revill; Ajantha Solomon; Fiona Wightman; Suha Saleh; Megan Crane; Paul U Cameron; Scott Bowden; Tin Nguyen; Cândida F Pereira; Paul V Desmond; Stephen A Locarnini; Sharon R Lewin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

Review 3.  What is expected from the pathologist in the diagnosis of viral hepatitis?

Authors:  Helmut Denk
Journal:  Virchows Arch       Date:  2011-02-26       Impact factor: 4.064

4.  HIV variability in the liver and evidence of possible compartmentalization.

Authors:  Jason T Blackard; Gang Ma; Christina M Martin; Susan D Rouster; M Tarek Shata; Kenneth E Sherman
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-04       Impact factor: 2.205

Review 5.  A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.

Authors:  Ameer Abutaleb; Kenneth E Sherman
Journal:  Hepatol Int       Date:  2018-09-20       Impact factor: 6.047

6.  Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis.

Authors:  Ana C Tuyama; Feng Hong; Yedidya Saiman; Chuansheng Wang; Derya Ozkok; Arevik Mosoian; Ping Chen; Benjamin K Chen; Mary E Klotman; Meena B Bansal
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

7.  Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling.

Authors:  Amy D Paulino; Kiren Ubhi; Edward Rockenstein; Anthony Adame; Leslie Crews; Scott Letendre; Ronald Ellis; Ian P Everall; Igor Grant; Eliezer Masliah
Journal:  J Neurovirol       Date:  2011-06-10       Impact factor: 2.643

8.  Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens.

Authors:  E Kainne Dokubo; Jennifer Evans; Valerie Winkelman; Sherri Cyrus; Leslie H Tobler; Alice Asher; Alya Briceno; Kimberly Page
Journal:  J Clin Virol       Date:  2014-01-27       Impact factor: 3.168

9.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.

Authors:  Bill G Kapogiannis; Erin Leister; George K Siberry; Russell B Van Dyke; Bret Rudy; Patricia Flynn; Paige L Williams
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

10.  Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.

Authors:  Xiaozhen Zhang; Astrid C Frank; Christine M Gille; Marybeth Daucher; Juraj Kabat; Steven Becker; Richard A Lempicki; Karoll J Cortez; Michael A Polis; G Mani Subramanian; Shyam Kottilil
Journal:  Hepatol Res       Date:  2009-09-25       Impact factor: 4.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.